Martin Naradikian

Lab Head

Biogen (Switzerland)

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Martin Naradikian is a Lab Head at Novartis in Switzerland. His research specializes in the intersection of machine learning and immunotherapy, with a focus on neoantigens and T cell responses in cancer treatment. Recent publications highlight his work on predicting functional genomic impacts and developing targeted cancer therapies.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (4)

Elizabeth Brunk

University of North Carolina at Chapel Hill

UNITED STATES

View details

Agnes Hamburger

UNITED STATES

View details

Bjoern Peters

Full Professor

La Jolla Institute for Allergy and Immunology

UNITED STATES

View details

Stephanie Ting

University of North Carolina at Chapel Hill

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Martin Naradikian

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Machine Learning of Three-Dimensional Protein Structures to Predict the Functional Impacts of Genome Variation

A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer.

Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells

Author Correction: Neoantigen-specific stem cell memory-like CD4<sup>+</sup> T cells mediate CD8<sup>+</sup> T cell-dependent immunotherapy of MHC class II-negative solid tumors.

Neoantigen-specific stem cell memory-like CD4<sup>+</sup> T cells mediate CD8<sup>+</sup> T cell-dependent immunotherapy of MHC class II-negative solid tumors.

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.

HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen.

The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans.

Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.

Collaborators (4)

Elizabeth Brunk

Agnes Hamburger

Bjoern Peters

Stephanie Ting

Make your next move.